logo-loader
viewCello Health PLC

Cello Health Plc expects to hit expectations for 2018 after 'excellent year'

Mark Scott, chief executive of Cello Health plc (LON:CLL), spoke to Proactive London's Andrew Scott following the release of their pre-close trading statement for 2018.

Strong like-for-like growth at its big pharma consultancy division, known as health, offset a slower outcome from brand and marketing operation Signal.

The health division also saw good like-for-like gross profit growth and better-operating margins.

Quick facts: Cello Health PLC

Price: 127.5 GBX

AIM:CLL
Market: AIM
Market Cap: £135.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cello Health PLC named herein, including the promotion by the Company of Cello Health PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Cello Health reports good growth in profits and strong cash flow

Cello Health PLC's (LON:CLL) Mark Scott tells Proactive London they've seen good growth in profits and strong cash flow for the first half of the year said that he's confident about the rest of the year too. The group delivered net revenue of £54.5mln for the first six months of the year,...

on 18/9/19

RNS

Holding(s) in Company

1 week, 6 days ago

Total Voting Rights

1 week, 6 days ago

Disposal

2 weeks, 4 days ago

Interim Results

on 18/9/19

Acquisition of ISS

on 16/8/19

2 min read